Market Cap 181.78M
Revenue (ttm) 114.70M
Net Income (ttm) -56.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.29%
Debt to Equity Ratio 0.00
Volume 2,464,700
Avg Vol 1,680,222
Day's Range N/A - N/A
Shares Out 227.22M
Stochastic %K 78%
Beta 1.88
Analysts Strong Sell
Price Target $7.46

Latest News on GOSS

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sep 10, 2024, 1:25 AM EDT - 8 months ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss


Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.


Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer


Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore


Gossamer Bio Announces $120 Million Private Placement Financing

Jul 13, 2022, 7:15 AM EDT - 3 years ago

Gossamer Bio Announces $120 Million Private Placement Financing


Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Apr 25, 2022, 9:06 AM EDT - 3 years ago

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program